Group 1 - The core issue involves allegations of misdiagnosis and missed cancer detection by Aikang Guobin, as a lawyer claims to have undergone health check-ups for ten years without being informed of cancer risks, leading to a late-stage cancer diagnosis in 2024 [1] - Aikang Guobin has acknowledged receipt of the lawyer's letter and is currently discussing how to address the situation, but has not provided a direct response regarding the allegations of misdiagnosis or missed diagnoses [1] - The company, Aikang Guobin, was established in September 2004 with a registered capital of 50 million RMB, and its business scope includes hospital management, corporate management, and health consulting services [1] Group 2 - Aikang Guobin has faced multiple medical disputes, including a lawsuit in May 2023 related to a contract dispute over a health check fee and damages due to missed diagnoses [2] - In March 2025, a subsidiary of Aikang Guobin was fined for failing to comply with medical record writing standards and for issues related to the quality of health check reports [2] - The CEO of Aikang Guobin previously highlighted industry issues, claiming that some institutions engage in fraudulent practices, such as having nurses impersonate doctors and discarding blood samples after testing [2][3]

近日，北京美年健康（002044）公益基金会(以下简称：美年健康公益基金会)第一届理事会第一次会议 在宁波召开。会议全程严格遵循法定程序，审议通过基金会章程，选举产生基金会理事长、副理事长、 秘书长和监事，审议通过基金会2025年下半年工作规划，以规范化运作为基础，标志着美年健康公益基 金会正式开始运营。 根据规划，基金会将锚定四大公益方向精准发力：在弱势群体健康关爱领域，持续深耕"爱无疆公益助 残"、"打工妈妈健康关爱"、"退役军人健康关爱"、"新业态劳动者健康关爱"、"爱老敬老健康关 爱"及"乡村教师健康关爱"等六大公益IP，通过专业化、系统化的服务，为困境群体筑牢健康保障；聚 焦疾病早筛攻坚，启动阿尔茨海默病早筛公益项目；在健康知识科普方面，整合三甲医院权威专家资 源，打造高质量健康科普品牌"美年健康专家课"；在健康生活方式倡导领域，依托"美年健康益起跑"小 程序，创新采用公益跑里程兑换体检服务模式，深度融合运动健康、公益慈善与个人健康管理理念，推 动全民健康意识提升。 美年健康表示，美年健康公益基金会的成立，既是集团积极响应健康公益行业共识的重要举措，更 让"大健康即公益"的理念有了实体载体。美年健康 ...

Meeting Announcement - The company will hold its first extraordinary general meeting of shareholders in 2025 on July 28, 2025, at 14:50 in Shanghai [1][2] - The meeting will combine on-site voting and online voting, with online voting available from 9:15 to 15:00 on the same day [1][2] Voting Procedures - Shareholders can choose either on-site voting or online voting, and duplicate votes will be counted based on the first submission [2] - Shareholders must register to attend the meeting, with specific requirements for both corporate and individual shareholders [6][7] Agenda Items - The meeting will review several proposals, including the issuance of shares for asset acquisition and related transactions [4][12] - Proposals require a two-thirds majority of valid votes from attending shareholders, with related shareholders required to abstain from voting on certain items [6][12] Compliance and Reporting - The proposals have been approved by the company's board and supervisory committee, and details were published in various financial news outlets [5][12] - The company will ensure compliance with relevant regulations regarding asset restructuring and share issuance [5][13]

Core Insights - The report highlights the increasing health issues among the population in Beijing, emphasizing the importance of regular health check-ups [1][2][8] - The data collected from 1.483 million health check-ups reveals alarming trends in various health indicators, particularly among different age groups and genders [1][5] Group 1: Health Issues Identified - Bone density reduction/osteoporosis has become the leading health concern in Beijing, with a detection rate of 53.64% [2] - The detection rate for increased Body Mass Index (BMI) and thyroid nodules also exceeds 50%, marking them as significant health threats [2] - Fatty liver, carotid artery abnormalities, and elevated total cholesterol levels have detection rates above 30% [2] Group 2: Gender-Specific Health Trends - Male participants show a higher prevalence of increased BMI, with detection rates nearing 70%, and a fatty liver detection rate of 55.11% among men aged 40-49 [5] - In contrast, females have a higher detection rate of thyroid nodules at over 57%, with a significant increase in breast nodules from 25.33% in 2021 to 40.53% [5] Group 3: Cancer Detection Rates - Thyroid cancer has the highest detection rate among the cancer cases identified, exceeding 48%, with a total of 1,535 cancer diagnoses among the health check-up participants [8] - The cancer detection rate among individuals under 40 years old is concerning, with nearly one-third of the diagnosed cases falling into this age group [8] - The report suggests that the high detection rate of thyroid cancer is due to the widespread use of ultrasound in health check-ups, with a participation rate of 78.85% for thyroid ultrasounds [8]

投资者提问：想请问公司未来是否有与公立三甲医院开展合作的规划？若能获得公立三甲医院对公司体 检结果的认可，将有助于公司在团体客户、健康管理等领域拓展更多业务合作。能否透露公司在这方面 的战略布局及推进计划？ 证券之星消息，美年健康(002044)06月18日在投资者关系平台上答复投资者关心的问题。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 美年健康回复：尊敬的投资者，您好！公司持续积极推动与公立三甲医院的交流合作。截止目前，公司 各地分院与当地三甲医院等机构共建超过350个医联体/健联体，在技术交流、医疗设备和专家资源共 享、人才培养、患者转诊、应急救援等方面开展合作。在结果互认方面，公司每年结合各地政策情况， 积极参与推动检验结果互认的有关工作，目前公司旗下数十家分院获选省、市级临床检验结果互认机 构，部分分院获选省、市级超声结果互认机构与放射结果互认机构。未来，公司继续积极响应政策号 召，持续积极参与推进更多分院医疗检查检验结果互认工作，为就医流程优化和用户体验升级不懈努 力。同时，公司将持续深化学科建设，加强与三甲医院、 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002044 证券简称：美年健康 公告编号：2025-028 美年大健康产业控股股份有限公司 3、会议召开的合法、合规性：本次股东大会的召集、召开及审议事项符合《中华人民共和国公司法》 《中华人民共和国证券法》《深圳证券交易所股票上市规则》等法律、行政法规及《公司章程》等规 定，提案内容明确并在法定期限内公告。 4、会议召开的日期、时间： （1）现场会议召开时间：2025年5月14日（星期三）下午14:30。 关于召开2024年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 美年大健康产业控股股份有限公司（以下简称"公司"）2024年度股东大会现场会议的召开地点为上海市 静安区灵石路697号健康智谷9号楼三楼公司会议室，敬请投资者特别留意。 根据公司于2025年4月15日召开的第九届董事会第八次会议，定于2025年5月14日召开公司2024年度股东 大会，本次股东大会将采用股东现场记名投票与网络投票表决相结合的方式召开，《关于召开2024年度 股东大会的通知》（公告 ...

Core Insights - The article highlights significant consumer complaints against Aikang Guobin, primarily related to aggressive marketing practices and inaccurate health examination results [1][3] - Aikang Guobin's reputation has been further tarnished by past scandals involving misleading health check practices, as revealed by the company's CEO [5][8] Group 1: Consumer Complaints - Over 1200 complaints have been filed against Aikang Guobin on the Black Cat platform, with most complaints focusing on excessive marketing and inaccurate test results [1] - A consumer reported a case where they paid 1200 yuan for genetic testing, but did not receive the promised follow-up consultation regarding their test results [1] - Another consumer shared a distressing experience where a health check indicated no major issues, but later led to a cancer diagnosis, resulting in significant medical expenses [3] Group 2: Industry Issues - In December 2018, Aikang Guobin's CEO revealed a scandal regarding "fake health checks" in the industry, indicating that many companies prioritize low costs over quality [5] - The CEO also mentioned that some health centers may employ nurses to perform ultrasound tests instead of qualified doctors, raising concerns about the accuracy of health assessments [8] - Following the CEO's revelations, Aikang Guobin faced scrutiny for discrepancies between health examination reports and actual medical conditions, prompting the company to promise refunds for erroneous tests [8]

Core Viewpoint - Meinian Health has reported strong growth in its AI-driven healthcare services, with Q1 2025 revenue reaching 1.754 billion yuan, including over 54 million yuan from AI technology, marking a 71.76% increase year-on-year, indicating a significant shift from technological exploration to large-scale application in the "AI + healthcare" model [1] Group 1: AI Empowerment in Health Management - Meinian Health's core strategy revolves around "AI + healthcare," transforming the entire health check process into an intelligent service system, covering pre-examination, examination, and post-examination stages [1] - In the pre-examination phase, AI technology customizes health check packages based on individual and group client data, ensuring precision and relevance in health assessments [2] - During the examination, the company has implemented intelligent management tools that enhance customer experience and facilitate seamless transitions from routine screenings to precise diagnostics [2] - Post-examination services leverage AI systems like "Health Xiaomei" to provide personalized health management, with significant improvements in report accuracy and processing efficiency [2] Group 2: Innovation and Competitive Advantage - Meinian Health focuses on building eight core disciplines, utilizing AI to create unique competitive barriers, particularly in ultrasound technology [3] - The company has introduced specialized AI products for various health management areas, enhancing screening efficiency and promoting systematic solutions for early detection [4] - Innovative screening models, such as the "CT One Scan Multiple Checks" system, integrate multiple assessments into a single examination, significantly improving efficiency [4] Group 3: Expansion of Post-Examination Market - The company is transitioning from traditional health check services to comprehensive lifecycle health management, activating deeper individual client needs through innovative operational strategies [5] - Meinian Health is enhancing customer engagement by providing a one-stop solution that includes health checks, specialized examinations, health management, and insurance [6] Group 4: Industry Impact and Future Outlook - Meinian Health is evolving from a health check service provider to an AI health management solution platform, establishing a dual engine for performance growth through specialized early screening products and intelligent health management [7] - The company aims to leverage AI technology to expand into trillion-level markets, focusing on senior health, health management, and data elements, positioning itself as a leader in the digital health management era [8]

Group 1 - The company announced plans to acquire 19 health check institutions, increasing its control over these entities to 100% for 18 of them and 90% for one [1] - The total unaudited revenue for these 19 institutions in 2024 is projected to be 505 million, with a net profit of 52 million, resulting in a net profit margin of 10.26% [2] - The acquisition is expected to enhance the company's performance by increasing the number of controlled outlets and overall revenue [2] Group 2 - The company has initiated a comprehensive transformation since 2020, focusing on building a health industry ecosystem and has proposed an "All in AI" strategy in 2023 [2] - The company utilizes AI as a core tool to develop a digital management platform for health check services, enhancing the quality management system across the entire process [2] - The company has introduced innovative products targeting key medical disciplines, particularly in cancer early screening, to meet deep health check demands [2] Group 3 - The company has not adjusted its profit forecasts due to the unaudited performance of the acquired institutions, with projected revenues for 2024-2026 being 10.599 billion, 11.614 billion, and 12.731 billion respectively [3] - Expected net profits for 2024-2026 are projected to be 349 million, 562 million, and 798 million respectively, with growth rates of -31.0%, 61.2%, and 42.0% [3] - The corresponding price-to-earnings ratios for 2025-2026 are estimated to be 38 and 27 times, maintaining a "buy" rating [3]

Core Viewpoint - Meinian Health plans to issue shares to acquire equity stakes in 19 health examination centers that are either partially or fully owned by listed companies, expanding its existing business in health examination services [1] Group 1: Acquisition Details - The company intends to purchase equity stakes from 14 companies, including Hengyang Meinian, and minority stakes from 5 subsidiaries, including Zhengzhou Meijian [1] - The specific transaction price for this acquisition has not yet been determined [1] Group 2: Business Expansion - The acquisition will allow the company to directly and indirectly hold 100% equity in multiple health examination centers across various locations, including Hengyang, Ningde, Yantai, Wuhan, and others [1] - The company will also hold 90% equity in Anxi Meinian as part of this transaction [1]